MedPath

Photocil (Topical) for the Treatment of Psoriasis Vulgaris

Not Applicable
Completed
Conditions
Psoriasis
Interventions
Drug: Photocil for Psoriasis
Other: Placebo - Sunscreen (SPF 2)
Registration Number
NCT01916629
Lead Sponsor
Applied Biology, Inc.
Brief Summary

Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight. Photocil is intended to help protect users from non-therapeutic Ultraviolet B (UVB) radiation while selectively passing wavelengths of light in the NB-UVB range with peak transmission of 308nm. The aim of the study is to assess the safety and efficacy of Photocil in the treatment of psoriasis

Detailed Description

NB-UVB phototherapy is a common treatment for patients with psoriasis, and has been reported to be safe and effective in numerous clinical trials. Clinical trials have reported achievement of Psoriasis Area Severity Index (PASI)-75 in 50-70% of patients after 4-6 weeks of NB-UVB treatment.

Many drawbacks limit patients compliance, access, and acceptance of traditional NB-UVB phototherapy. The strict treatment regimen (2-3 sessions per week for an average of 12 weeks or more) performed at a specialized phototherapy clinic combined with high cost and low or no reimbursement make compliance and access a major drawback.

In order to address the drawbacks of phototherapy, we developed a novel topical cream - Photocil - that selectively delivers NB-UVB therapy when exposed to sunlight. When used with natural sunlight, Photocil provides a convenient alternative to traditional clinic based phototherapy; thus, has the potential to dramatically increase patient compliance and treatment outcome.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • Diagnosed with psoriasis vulgaris confirmed by a dermatologist
  • Psoriasis lesions affecting at a minimum 5% of the facial, legs, or arms surface area
  • Age: 18 to 65
  • Participants able to give informed consent
Exclusion Criteria
  • Subject did not respond to prior phototherapy treatment
  • Subject completed phototherapy for same lesion(s) in last 6 months
  • Subject has previous history of skin cancer
  • Subject has previous history of photosensitivity
  • Subject has a history of herpes (HSV I or II) outbreaks
  • Subject has previous history of autoimmune disease may be excluded at investigator's discretion
  • Subject is currently taking of immunosuppressive or photosensitizing drugs
  • Subject plans to use antibiotics, anti-fungal, calcineurin inhibitors or other drugs that may cause photosensitivity during the study period. These patients may be excluded at investigator's discretion
  • Subject is pregnant or lactating women

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Photocil for PsoriasisPhotocil for PsoriasisActive Drug - Photocil for Psoriasis
Placebo - Sunscreen (SPF 2)Placebo - Sunscreen (SPF 2)Placebo - Sunscreen (SPF 2)
Primary Outcome Measures
NameTimeMethod
Percent Lesion Clearance90 days
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Physicians Institute

🇺🇸

Tucson, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath